Principal Scientist, Toxicology
![]() | |
![]() United States, Massachusetts, Cambridge | |
![]() 675 West Kendall Street (Show on map) | |
![]() | |
Overview:
We are seeking a highly motivated individual with drug development and regulatory toxicology experience to join our expanding Toxicology group within our Early Development (eDEV) functional area. Candidates should have doctoral level research training in toxicology or related discipline and preferably be board-certified in general toxicology (DABT). The candidate will develop the regulatory toxicology strategy for selected programs, design and supervise internal and contract laboratory studies, review and finalize reports, and interpret and integrate all nonclinical findings, and then summarize into regulatory submissions. For early-stage programs, the successful candidate will assess target associated toxicities, identify the potential toxicity and define the therapeutic index of product development candidates. For development and clinical-stage programs, he/she will lead all regulatory toxicology activities for assigned programs. An additional key role for this position will be to represent the Early Development functional area on assigned drug development program teams. This position is onsite and will be primarily located in Cambridge, MA. Key Responsibilities The successful candidate will have a key role in developing regulatory toxicology strategies and providing deep scientific interpretation of nonclinical findings as to their relevance and translation into clinical and regulatory development. The role will involve overseeing the conduct of non-GLP screening toxicity studies and managing externallyconducted GLP toxicology studies to support development of multiple drug candidates in Alnylam's industry-leading RNAi Therapeutics pipeline.
Qualifications:
About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. > |